Medicine and Dentistry
Glioblastoma
100%
Implant
50%
Dosimetry
50%
Magnetic Resonance Imaging
50%
Brachytherapy
50%
6 O Methylguanine
50%
Heterozygosity
50%
Biological Marker
50%
DNA Methyltransferase
50%
Isocitrate Dehydrogenase 1
50%
Dendritic Cell Immunotherapy
50%
Methylation
33%
Promoter Region
33%
Edema
25%
Multiple Linear Regression Analysis
25%
Ganglioglioma
21%
Molecular Marker
16%
Side Effect
14%
Prospective Study
14%
Overall Survival
14%
Dose Calculation
12%
Dose-Volume Histogram
12%
X-Ray Imaging
12%
Magnetic Resonance Imaging
12%
Neoplasm
7%
Adverse Event
7%
Phase I Trials
7%
Clinical Trial
7%
Phase II Trials
7%
Phase III Trials
7%
Dendritic Cell Vaccine
7%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
100%
Isocitrate Dehydrogenase 1
50%
DNA Methyltransferase
50%
Immunotherapy
50%
6 O Methylguanine
50%
Biological Marker
50%
Molecular Marker
16%
Overall Survival
14%
Side Effect
14%
Prospective Study
14%
Phase III Trials
7%
Adverse Event
7%
Neoplasm
7%
Dendritic Cell Vaccine
7%
Clinical Trial
7%
Phase I Trials
7%
Phase II Trials
7%
Biochemistry, Genetics and Molecular Biology
O-6-Methylguanine-DNA Methyltransferase
50%
Loss of Heterozygosity
50%
Isocitrate Dehydrogenase
50%
Dendritic Cell
50%
Methylation
33%
Promoter Region
33%
Overall Survival
25%
Prospective Study
25%
Molecular Biology
16%
Genetic Marker
16%
Phase III Trials
12%
Phase II Trials
12%
Cell Lysate
12%
Clinical Trial
12%
Phase I Trials
12%